We are closely monitoring Storm Hernando, which is forecast to impact the Boston/Houston area. We would like to reassure you 2nd TRP Target Selection & Drug Design Summit 2026 will go ahead in-person, as planned.

However, we understand that individual travel plans could be affected, in particular expected international and domestic flight disruption. If you experience any travel disruptions or delays, please let us know as soon as possible so we can support you where we can.

Please also note:

  • You may see increased Uber/Lyft pricing due to weather conditions.
  • We recommend allowing extra time for travel to the venue.

We will continue to monitor the situation closely and will communicate promptly should anything change. Please keep an eye on your emails from hansonwade.com.

Thank you for your understanding, stay safe and we look forward to welcoming you to 2nd TRP Target Selection & Drug Design Summit 2026

Venue

This year's event will be held in Boston, MA at The Colonnade.

venue image
venue image
venue image

Accommodation

Browse our hotel deals for the 2nd TRP Target Selection & Drug Design Summit 2026.

Warning: Unsolicited Accommodation Calls/Emails to Hanson Wade Group Attendees

It has been brought to our attention that there are multiple third-party companies contacting our conference attendees claiming to represent Hanson Wade and/or one of our conference brands with fraudulent hotel booking schemes. Please review our accommodation policy here for the full details: Accommodation Policy - Hanson Wade Group.

explore the agenda image
Explore the Agenda

Discover how the field’s leaders are redefining target selection, isotope pairing, and translational strategy to unlock the next era of radioligand therapy.

partner with us image
Partner With Us

Connect with RLT decision-makers searching for partners in targeting, imaging, radiochemistry, and isotopes to drive faster, safer radiopharmaceutical development.

join experts image
Join RLT Experts

Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.